Difference between revisions of "Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5 (Q9818)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: title (P93): Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma, #quickstatements; #temporary_batch_1590010982689)
(‎Created claim: Page(s) (P105): 823-829, #quickstatements; #temporary_batch_1590074839150)
 
Property / Page(s)
 +
823-829
Property / Page(s): 823-829 / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Riechelmann H
    0 references
    0 references
    2008
    0 references
    Oral. Oncol.
    0 references
    44
    0 references
    Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
    0 references
    823-829
    0 references